|
|
Article: Maxim Pharmaceuticals Announces Collaboration With BioNative AB; Phase II Trial of Maxamine Therapy for the Treatment of Renal Cell Carcinoma Planned for Fall 1998.
- Article from:
- Business Wire
- Article date:
- September 14, 1998
CopyrightCOPYRIGHT 1998 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO--(BW HealthWire)--Sept. 14, 1998--Maxim Pharmaceuticals (AMEX:MMP)(SSE:MAXM) today announced that it has entered into a collaboration with BioNative AB to test Maxamine(TM) in a Phase II trial of patients with renal cell carcinoma (RCC) in combination with BioNative's natural cytokine, Interferon Alfanative(R).
"We are pleased to collaborate with BioNative on this trial," said Larry Stambaugh, president and chief executive officer. "Renal cell carcinoma represents another important clinical need where Maxamine Therapy(TM) has the potential to increase survival while maintaining the patient's quality of life. In addition, this trial gives us the ...